Finally, the identification, cloning and characterization of thrombopoietin as the primary regulator of platelet production, as well as a critical effector of HSC biology, have led to its clinical development for patients with thrombocytopenia of several origins, as well as aplastic anemia. This evidence concerns the gene THPO and idiopathic aplastic anemia.